2006
Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B. Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry 2006, 61: 545-550. PMID: 16730335, DOI: 10.1016/j.biopsych.2006.02.032.Peer-Reviewed Original ResearchConceptsRisperidone-induced increasesLong-term risperidone treatmentProlactin levelsRisperidone treatmentSerum prolactinOpen-label followWeeks of risperidoneBaseline prolactin levelsEffects of ShortPlacebo groupProlactin elevationReceptor polymorphismsWeek 8Baseline levelsMean increaseProlactinRisperidoneSerum samplesAdverse effectsPlaceboChildrenTreatmentMonthsDRD2 allelesAdolescents
1990
Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder
Shaywitz B, Shaywitz S, Sebrechts M, Anderson G, Cohen D, Jatlow P, Young J. Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Sciences 1990, 46: 625-633. PMID: 2308471, DOI: 10.1016/0024-3205(90)90131-a.Peer-Reviewed Original Research
1989
Neurochemical Study of Dopamine Functioning in Autistic and Normal Subjects
MINDERAA R, ANDERSON G, VOLKMAR F, AKKERHUIS G, COHEN D. Neurochemical Study of Dopamine Functioning in Autistic and Normal Subjects. Journal Of The American Academy Of Child & Adolescent Psychiatry 1989, 28: 190-194. PMID: 2925571, DOI: 10.1097/00004583-198903000-00007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAutistic DisorderDopamineFemaleHomovanillic AcidHumansMalePhenothiazinesProlactinConceptsPlasma PRLPlasma prolactinHVA levelsUrinary HVANormal controlsNormal subjectsUrinary DA excretionUrinary HVA excretionHomovanillic acid levelsDose of neurolepticPlasma PRL valuesDopamine functioningDopamine excretionNeuroleptic doseHVA excretionNeuroleptic medicationDA excretionNeurochemical studiesPRL valuesPeripheral indicesExcretion rateAcid levelsHVAExcretionSignificant differences
1982
Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
Shaywitz S, Hunt R, Jatlow P, Cohen D, Young J, Pierce R, Anderson G, Shaywitz B. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982, 69: 688-94. PMID: 7079034, DOI: 10.1542/peds.69.6.688.Peer-Reviewed Original ResearchConceptsAcute studyMPH concentrationsGrowth hormoneObserved maximal concentrationCentral dopaminergic mechanismsPeak plasma concentrationAdministration of medicationsPharmacokinetics of methylphenidatePlasma growth hormoneConcentrations of methylphenidatePlasma MPH concentrationsAttention deficit disorderClinical responseChronic treatmentDopaminergic mechanismsGroup of childrenDisorders of attentionAbbreviated Conners' Rating ScaleSchool-aged childrenOral administrationPlasma concentrationsClinical pharmacologyMPH administrationProlactin concentrationsPercentage of improvement
1981
Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report
Young J, Cohen D, Hattox S, Kavanagh M, Anderson G, Shaywitz B, Maas J. Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report. Life Sciences 1981, 29: 1467-1475. PMID: 6946271, DOI: 10.1016/0024-3205(81)90012-6.Peer-Reviewed Original ResearchConceptsFree MHPGPlasma free MHPGTourette syndromeChallenge doseNeuroendocrine responsesDoses of clonidineSingle oral dosesClonidine administrationResponsive patientsGH responseOral dosesMaintenance treatmentThyroxine indexClonidineTS patientsPatientsMHPGSyndromeT patientsNeuropsychiatric patientsPilot studyPreliminary reportMetabolic responseFurther investigationDose